INOVIQ Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IIQ.AX research report →
Price Chart
About the company
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer.
- CEO
- Leearne Maree Hinch
- IPO
- 1988
- Employees
- 15
- HQ
- Notting Hill, VIC, AU
Get TickerSpark's AI analysis on IIQ.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $26.04M
- P/E
- -3.01
- Fwd P/E
- 0.88
- PEG
- -0.24
- P/S
- 21.41
- P/B
- 1.02
- EV/EBITDA
- -1.59
- Div Yield
- 0.00%
- Gross Margin
- -47.93%
- Op Margin
- -834.20%
- Net Margin
- -594.92%
- ROE
- -37.14%
- ROIC
- -36.44%
Latest fiscal year · YoY change
- Revenue
- $1.82M+239.2%
- Gross Profit
- $-1,559,625-443.5%
- Op Income
- $-10,598,576
- Net Income
- $-6,932,280-5.8%
- EPS
- $-0.06+12.1%
- OCF Growth
- -7.9%
- FCF Growth
- -6.0%
- 52W High
- $0.56
- 52W Low
- $0.18
- 50D MA
- $0.27
- 200D MA
- $0.33
- Beta
- 1.55
- RSI (14)
- 38
- Avg Volume
- 359.93K
No earnings-call transcripts are available for IIQ.AX yet.
- Free Float
- 82.4%
- Shares Outstanding
- 140.78M
- Float Shares
- 115.94M
Our IIQ.AX coverage
Recent articles, reports, and earnings notes.
No research on IIQ.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IIQ.AX report →